Abstract

In this study, we established a nomogram for the prognostic prediction of patients with early-onset cervical cancer (EOCC) for both overall survival (OS) and cancer-specific survival (CSS). The Surveillance, Epidemiology, and End Results (SEER) database was used to identify 10,079 patients diagnosed with EOCC between 2004 and 2015; these cases were then randomly divided into training and validation sets. The independent prognostic factors were identified in a retrospective study of 7,055 patients from the training set. A prognostic nomogram was developed using R software according to the results of multivariable Cox regression analysis. Furthermore, the model was externally validated using the data from the remaining 3,024 patients diagnosed at different times and enrolled in the SEER database. For the training set, the C-indexes for OS and CSS prediction were determined to be 0.831 (95 % confidence interval [CI]: 0.815–0.847) and 0.855 (95 % CI: 0.839–0.871), respectively. Receiver operating characteristic (ROC) analysis has revealed that the nomograms were a superior predictor compared with TNM stage and SEER stage. The areas under the curve (AUC) of the nomogram for OS and CSS prediction in the ROC analysis were 0.855 (95 % CI: 0.847–0.864) and 0.782 (95 % CI: 0.760–0.804), respectively. In addition, calibration curves indicated a perfect agreement between the nomogram-predicted and the actual 1-, 3-, and 5-year OS and CSS rates in the validation cohort. Thus, in this study, we established and validated a prognostic nomogram that provides an accurate prediction for 3-, 5-, and 10-year OS and CSS of EOCC patients. This will be useful for clinicians in guiding counseling and clinical trial design for cervical cancer patients.

Highlights

  • Cervical cancer remains the fourth most common female malignancy in the world [1,2], ranking second as the leading cause of cancer-related deaths in young women aged 20 to 39 years in 2020 [1]

  • 10,079 eligible patients, who were diagnosed as having early-onset cervical cancer (EOCC) from 2004 to 2015, were identified in the SEER

  • Www.bjbms.org database; these cases were randomly divided into a training set (n = 7,055) and a validation set (n = 3,024)

Read more

Summary

Introduction

Cervical cancer remains the fourth most common female malignancy in the world [1,2], ranking second as the leading cause of cancer-related deaths in young women aged 20 to 39 years in 2020 [1]. Surgery, radiotherapy, chemotherapy, and immunotherapy serve as the primary treatments for this type of cancer [5]. Patients younger than 45 years old are defined as having early-onset cervical cancer. Significant progress has been made in surgery, radiotherapy, and chemotherapy for treating cervical. Accurate prognostic markers and improved individualized treatment are needed

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.